請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85240
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊雅倩(Ya-Chien Yang) | |
dc.contributor.advisor | 楊雅倩(Ya-Chien Yang | ycyangntu@ntu.edu.tw | ), | |
dc.contributor.author | Hsin-Ting Lee | en |
dc.contributor.author | 李昕庭 | zh_TW |
dc.date.accessioned | 2023-03-19T22:52:19Z | - |
dc.date.copyright | 2022-10-13 | |
dc.date.issued | 2022 | |
dc.date.submitted | 2022-09-28 | |
dc.identifier.citation | 1. Dalal, N., et al., Omics technologies for improved diagnosis and treatment of colorectal cancer: Technical advancement and major perspectives. Biomed Pharmacother, 2020. 131: p. 110648. 2. Carethers, J.M. and B.H. Jung, Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology, 2015. 149(5): p. 1177-1190 e3. 3. De Rosa, M., et al., Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep, 2015. 34(3): p. 1087-96. 4. ML, D.E.M., et al., Desmoid Tumors in Familial Adenomatous Polyposis. Anticancer Res, 2017. 37(7): p. 3357-3366. 5. Steinke, V., et al., Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. Dtsch Arztebl Int, 2013. 110(3): p. 32-8. 6. Sinicrope, F.A., Lynch Syndrome-Associated Colorectal Cancer. N Engl J Med, 2018. 379(8): p. 764-773. 7. Stidham, R.W. and P.D.R. Higgins, Colorectal Cancer in Inflammatory Bowel Disease. Clin Colon Rectal Surg, 2018. 31(3): p. 168-178. 8. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 61(5): p. 759-67. 9. Pino, M.S. and D.C. Chung, The chromosomal instability pathway in colon cancer. Gastroenterology, 2010. 138(6): p. 2059-72. 10. Nguyen, H.T. and H.Q. Duong, The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol Lett, 2018. 16(1): p. 9-18. 11. Boland, C.R. and A. Goel, Microsatellite instability in colorectal cancer. Gastroenterology, 2010. 138(6): p. 2073-2087 e3. 12. Nojadeh, J.N., S. Behrouz Sharif, and E. Sakhinia, Microsatellite instability in colorectal cancer. EXCLI J, 2018. 17: p. 159-168. 13. Kang, S., et al., The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Medicine (Baltimore), 2018. 97(9): p. e0019. 14. Toyota, M., et al., CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A, 1999. 96(15): p. 8681-6. 15. Jia, M., et al., Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics, 2016. 8: p. 25. 16. Nazemalhosseini Mojarad, E., et al., The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench, 2013. 6(3): p. 120-8. 17. Weiser, M.R., AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol, 2018. 25(6): p. 1454-1455. 18. Shimoda, Y. and K. Watanabe, Contactins: emerging key roles in the development and function of the nervous system. Cell Adh Migr, 2009. 3(1): p. 64-70. 19. Zuko, A., et al., Contactins: structural aspects in relation to developmental functions in brain disease. Adv Protein Chem Struct Biol, 2011. 84: p. 143-80. 20. Bizzoca, A., P. Corsi, and G. Gennarini, The mouse F3/contactin glycoprotein: structural features, functional properties and developmental significance of its regulated expression. Cell Adh Migr, 2009. 3(1): p. 53-63. 21. Falk, J., et al., F3/contactin, a neuronal cell adhesion molecule implicated in axogenesis and myelination. Biol Cell, 2002. 94(6): p. 327-34. 22. Yoshihara, Y., et al., Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: four members of an axon-associated cell adhesion molecule subgroup of the immunoglobulin superfamily. J Neurobiol, 1995. 28(1): p. 51-69. 23. Kamei, Y., et al., Human NB-2 of the contactin subgroup molecules: chromosomal localization of the gene (CNTN5) and distinct expression pattern from other subgroup members. Genomics, 2000. 69(1): p. 113-9. 24. Mimmack, M.L., et al., A novel splice variant of the cell adhesion molecule BIG-2 is expressed in the olfactory and vomeronasal neuroepithelia. Brain Res Mol Brain Res, 1997. 47(1-2): p. 345-50. 25. Mayor, S. and H. Riezman, Sorting GPI-anchored proteins. Nat Rev Mol Cell Biol, 2004. 5(2): p. 110-20. 26. Kirov, G., CNVs in neuropsychiatric disorders. Hum Mol Genet, 2015. 24(R1): p. R45-9. 27. Torres, F., M. Barbosa, and P. Maciel, Recurrent copy number variations as risk factors for neurodevelopmental disorders: critical overview and analysis of clinical implications. J Med Genet, 2016. 53(2): p. 73-90. 28. Manderson, E.N., et al., Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. Int J Gynecol Cancer, 2009. 19(4): p. 513-25. 29. Sjoblom, T., et al., The consensus coding sequences of human breast and colorectal cancers. Science, 2006. 314(5797): p. 268-74. 30. Masson, A.L., et al., Copy number variation in hereditary non-polyposis colorectal cancer. Genes (Basel), 2013. 4(4): p. 536-55. 31. Boni, C., C. Laudanna, and C. Sorio, A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease. Biomolecules, 2022. 12(1). 32. Boni, C. and C. Sorio, The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer. Front Cell Dev Biol, 2021. 9: p. 768969. 33. Kastury, K., et al., Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation. Genomics, 1996. 32(2): p. 225-35. 34. Shu, S.T., et al., Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer Res, 2010. 30(6): p. 1937-46. 35. Cheung, A.K., et al., PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma. Oncotarget, 2015. 6(15): p. 13434-47. 36. Wang, Z., et al., Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 2004. 304(5674): p. 1164-6. 37. van Roon, E.H., et al., Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer. Eur J Hum Genet, 2011. 19(3): p. 307-12. 38. Bouyain, S. and D.J. Watkins, The protein tyrosine phosphatases PTPRZ and PTPRG bind to distinct members of the contactin family of neural recognition molecules. Proc Natl Acad Sci U S A, 2010. 107(6): p. 2443-8. 39. Nikolaienko, R.M., et al., Structural Basis for Interactions Between Contactin Family Members and Protein-tyrosine Phosphatase Receptor Type G in Neural Tissues. J Biol Chem, 2016. 291(41): p. 21335-21349. 40. Murphrey, M.B., L. Quaim, and M. Varacallo, Biochemistry, Epidermal Growth Factor Receptor, in StatPearls. 2022: Treasure Island (FL). 41. Ferguson, K.M., Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys, 2008. 37: p. 353-73. 42. Seshacharyulu, P., et al., Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets, 2012. 16(1): p. 15-31. 43. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2000. 103(2): p. 211-25. 44. Sigismund, S., D. Avanzato, and L. Lanzetti, Emerging functions of the EGFR in cancer. Mol Oncol, 2018. 12(1): p. 3-20. 45. Wee, P. and Z. Wang, Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel), 2017. 9(5). 46. Scaltriti, M. and J. Baselga, The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 2006. 12(18): p. 5268-72. 47. Koveitypour, Z., et al., Signaling pathways involved in colorectal cancer progression. Cell Biosci, 2019. 9: p. 97. 48. Bonamy, C., et al., Expression of the human antimicrobial peptide beta-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells. Sci Rep, 2018. 8(1): p. 18043. 49. He, W.L., et al., Association Between c-Myc and Colorectal Cancer Prognosis: A Meta-Analysis. Front Physiol, 2018. 9: p. 1549. 50. Hu, T. and C. Li, Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer, 2010. 9: p. 236. 51. Jeong, W.J., E.J. Ro, and K.Y. Choi, Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway. NPJ Precis Oncol, 2018. 2(1): p. 5. 52. Shang, S., F. Hua, and Z.W. Hu, The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget, 2017. 8(20): p. 33972-33989. 53. Rennoll, S. and G. Yochum, Regulation of MYC gene expression by aberrant Wnt/beta-catenin signaling in colorectal cancer. World J Biol Chem, 2015. 6(4): p. 290-300. 54. Bian, J., et al., Transcriptional Regulation of Wnt/beta-Catenin Pathway in Colorectal Cancer. Cells, 2020. 9(9). 55. Kobayashi, M., et al., Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer, 2000. 82(10): p. 1689-93. 56. Valenta, T., G. Hausmann, and K. Basler, The many faces and functions of beta-catenin. EMBO J, 2012. 31(12): p. 2714-36. 57. Katoh, M., Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol, 2017. 51(5): p. 1357-1369. 58. Kaidi, A., A.C. Williams, and C. Paraskeva, Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol, 2007. 9(2): p. 210-7. 59. Manolagas, S.C. and M. Almeida, Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol, 2007. 21(11): p. 2605-14. 60. Poulson, D.F., Chromosomal Deficiencies and the Embryonic Development of Drosophila Melanogaster. Proc Natl Acad Sci U S A, 1937. 23(3): p. 133-7. 61. Lehmann, R., et al., On the phenotype and development of mutants of early neurogenesis inDrosophila melanogaster. Wilehm Roux Arch Dev Biol, 1983. 192(2): p. 62-74. 62. Nickoloff, B.J., B.A. Osborne, and L. Miele, Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene, 2003. 22(42): p. 6598-608. 63. Borggrefe, T. and F. Oswald, The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci, 2009. 66(10): p. 1631-46. 64. Aster, J.C., W.S. Pear, and S.C. Blacklow, The Varied Roles of Notch in Cancer. Annu Rev Pathol, 2017. 12: p. 245-275. 65. Schafer, K.A., The cell cycle: a review. Vet Pathol, 1998. 35(6): p. 461-78. 66. Wang, Z., Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling. Cells, 2021. 10(12). 67. Barnum, K.J. and M.J. O'Connell, Cell cycle regulation by checkpoints. Methods Mol Biol, 2014. 1170: p. 29-40. 68. Foster, D.A., et al., Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). Genes Cancer, 2010. 1(11): p. 1124-31. 69. Stark, G.R. and W.R. Taylor, Analyzing the G2/M checkpoint. Methods Mol Biol, 2004. 280: p. 51-82. 70. Gorbsky, G.J., The mitotic spindle checkpoint. Curr Biol, 2001. 11(24): p. R1001-4. 71. I-Chien Lin., Study of contactin 4-mediated molecular mechanism in colorectal cancer. 2020, 國立臺灣大學醫學檢驗暨生物技術學研究所. 72. Shao-Yu Chiang,. Study of tumor suppressor functions of contactin 4 in colorectal cancer. 2015, 國立臺灣大學醫學檢驗暨生物技術學研究所. 73. Po-Lin Chen,. Study of Contactin 4-mediated changes in cellular energy metabolism in colorectal cancer. 2019, 國立臺灣大學醫學檢驗暨生物技術學研究所. 74. Wu, G.Y., K. Deisseroth, and R.W. Tsien, Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A, 2001. 98(5): p. 2808-13. 75. Leppa, S., et al., Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J, 1998. 17(15): p. 4404-13. 76. Morrison, D.K., MAP kinase pathways. Cold Spring Harb Perspect Biol, 2012. 4(11). 77. Wu, G. and X. He, Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation. Biochemistry, 2006. 45(16): p. 5319-23. 78. Peignon, G., et al., Complex interplay between beta-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut, 2011. 60(2): p. 166-76. 79. Ungerback, J., et al., The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells. PLoS One, 2011. 6(3): p. e17957. 80. Kaemmerer, E., et al., Targeting Wnt Signaling via Notch in Intestinal Carcinogenesis. Cancers (Basel), 2019. 11(4). 81. Borggrefe, T., et al., The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and hypoxia pathways. Biochim Biophys Acta, 2016. 1863(2): p. 303-13. 82. Bretones, G., M.D. Delgado, and J. Leon, Myc and cell cycle control. Biochim Biophys Acta, 2015. 1849(5): p. 506-16. 83. Siu, K.T., M.R. Rosner, and A.C. Minella, An integrated view of cyclin E function and regulation. Cell Cycle, 2012. 11(1): p. 57-64. 84. Diwanji, N. and A. Bergmann, An unexpected friend - ROS in apoptosis-induced compensatory proliferation: Implications for regeneration and cancer. Semin Cell Dev Biol, 2018. 80: p. 74-82. 85. Diwanji, N. and A. Bergmann, Two Sides of the Same Coin - Compensatory Proliferation in Regeneration and Cancer. Adv Exp Med Biol, 2019. 1167: p. 65-85. 86. Zhu, H., L. Nie, and C.G. Maki, Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem, 2005. 280(32): p. 29282-8. 87. Abbas, T. and A. Dutta, p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer, 2009. 9(6): p. 400-14. 88. Engeland, K., Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ, 2022. 29(5): p. 946-960. 89. Jung, Y.S., Y. Qian, and X. Chen, Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal, 2010. 22(7): p. 1003-12. 90. Yosef, R., et al., p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling. EMBO J, 2017. 36(15): p. 2280-2295. 91. Kumari, R. and P. Jat, Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. Front Cell Dev Biol, 2021. 9: p. 645593. 92. Oguro-Ando, A., et al., Cntn4, a risk gene for neuropsychiatric disorders, modulates hippocampal synaptic plasticity and behavior. Transl Psychiatry, 2021. 11(1): p. 106. 93. Breuss, J.M. and P. Uhrin, VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adh Migr, 2012. 6(6): p. 535-615. 94. Mahmood, N., C. Mihalcioiu, and S.A. Rabbani, Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol, 2018. 8: p. 24. 95. Waldner, M.J., S. Foersch, and M.F. Neurath, Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci, 2012. 8(9): p. 1248-53. 96. Lee, Y.S., et al., Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer, 2012. 106(11): p. 1833-41. 97. Fillmore, C.M., et al., EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature, 2015. 520(7546): p. 239-42. 98. Ren, J., et al., Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics, 2018. 8(14): p. 3932-3948. 99. Wirth, M., et al., High NOTCH1 mRNA Expression Is Associated with Better Survival in HNSCC. Int J Mol Sci, 2018. 19(3). 100. Baeten, J.T. and B. Lilly, Differential Regulation of NOTCH2 and NOTCH3 Contribute to Their Unique Functions in Vascular Smooth Muscle Cells. J Biol Chem, 2015. 290(26): p. 16226-37. 101. Kang, W., et al., NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway. Oncogene, 2021. 40(9): p. 1578-1594. 102. Nagamatsu, I., et al., NOTCH4 is a potential therapeutic target for triple-negative breast cancer. Anticancer Res, 2014. 34(1): p. 69-80. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85240 | - |
dc.description.abstract | 在我國,大腸直腸癌之發生率與死亡率歷年以來皆位居於前位,其主要源於致癌基因或抑癌基因之基因變異,導致腸黏膜上皮細胞的過度增生。本實驗室先前於人類第三號染色體3p26.3發現Contactin 4 (CNTN4)在大腸直腸癌可能作為抑癌基因。於HCT116細胞表現CNTN4得以抑制細胞增生、固著與非固著依賴性胞落形成能力,且CNTN4表現可以抑制裸鼠皮下腫瘤生長及減少血管新生,並假設CNTN4會與Protein tyrosine phosphatase receptor type gamma (PTPRG)相互作用後,抑制Erk1/2及其下游CREB和c-Jun之磷酸化。本論文欲藉由RNA-Sequencing (RNA-seq)結果,以不同生物資訊資料庫分析,探討CNTN4於大腸直腸癌細胞可能調控的分子機制。初步,利用Gene Set Enrichment Analysis (GSEA)做分析,指出CNTN4的表現與Epidermal growth factor receptor (EGFR)及NOTCH訊號傳遞路徑呈現顯著負相關。接續利用即時定量聚合酶連鎖反應與西方墨點法,驗證在大腸癌細胞株表現CNTN4後,EGFR之mRNA與蛋白質表現量皆有下降。目前已知,c-MYC的表現量會受上游EGFR透過Erk1/2所調控,並影響細胞增生,因此檢測而知c-MYC表現量與CNTN4表現明顯呈現負相關。另一方面,RNA-seq結果顯示WNT/β-catenin訊號傳遞路徑與CNTN4表現呈負相關,而β-catenin已知具有調控c-MYC轉錄的功能,於是進一步研究其表現與CNTN4之關聯,在HCT116及SW620細胞株表現CNTN4確實可降低-catenin之mRNA及蛋白表現量,且活化態之β-catenin也隨之減少,並將β-catenin滯留於細胞膜附近,減少其進入細胞核內,以降低下游基因轉錄。對於NOTCH相關路徑,初步已利用即時定量聚合酶連鎖反應檢測NOTCH1-NOTCH4於HCT116及HCT15單一穩定表現CNTN4細胞株之mRNA表現量,結果顯示,當CNTN4表現時,NOTCH1-NOTCH4 mRNA表現皆有下降趨勢。後續偵測Notch intracellular domain (NICD)及其下游目標基因之表現量,結果發現CNTN4會影響NOTCH訊號傳遞之活性。藉由RNA-seq基因富集分析指出CNTN4可能參與細胞週期之調控,也從文獻得知c-MYC會調控下游目標基因以影響細胞週期,實驗結果也發現於HCT116細胞株表現CNTN4,p21表現量上升並減少Rb磷酸化,進一步使細胞週期停滯於G0/G1時期。綜合而論,CNTN4透過調控細胞週期,並影響EGFR與NOTCH下游相關訊息路徑以減緩大腸直腸癌細胞生長。 | zh_TW |
dc.description.abstract | Colorectal cancer incidence has been rising worldwide. In our previous study, we delineated a minimal deletion region (MDR) at 3p26.2-p26.3 by using loss of heterozygosity study, followed by clinical relevance assessment of patients with colorectal cancer. Within the MDR, we proposed Contactin 4 (CNTN4), a cell adhesion protein, as a candidate tumor suppressor gene. CNTN4-expressing single stable clones were established in different CRC cell lines, and exhibited a decreased capability of cell proliferation and anchorage-dependent and independent colony formation, as well as reduced xenograft tumor growth in nude mice. Then, we purposed CNTN4 may mediate the tumor suppression through decreased the phosphorylation of CREB, c-Jun and ERK1/2. In the study, the CNTN4-mediated molecular mechanisms in HCT116 cells were explored by using RNA-sequencing. Furthermore, the differential genes expression between HCT116/Mock and HCT116/CNTN4-c7 cells was analyzed by RNA-sequencing to identify CNTN4-regulated genes and pathways. The enrichment analysis indicated that CNTN4 expression is negatively correlated to EGFR and NOTCH signaling pathway related genes. Consequently, we verified the inhibition of mRNA and protein levels with EGFR, c-MYC, β-catenin and NOTCH in CNTN4-expressing CRC cells. Furthermore, CNTN4 may inhibit β-catenin translocation into nucleus to decrease the activity and decrease the NOTCH intracellular domain expression to inactivate the signal transduction. According to the gene enrichment analysis, we also monitored the DNA content to identify the cell cycle progression. The results indicated that CNTN4 may retard cell cycle into G0/G1 phase by mediating p21 expression and Rb phosphorylation level. Taken together, CNTN4 is a novel tumor suppressor through modulating EGFR-associated signaling pathway to reduce downstream molecules phosphorylation level and thus decrease related-transcription factor expression, in addition retardant cell cycle to decrease cell proliferation in colorectal cancer. | en |
dc.description.provenance | Made available in DSpace on 2023-03-19T22:52:19Z (GMT). No. of bitstreams: 1 U0001-2709202212424700.pdf: 10614028 bytes, checksum: b2b72097197339251f6c025731dfbcdb (MD5) Previous issue date: 2022 | en |
dc.description.tableofcontents | 致謝 i 摘要 ii Abstract iv 縮寫對照表 vi 目錄 ix 圖目錄 xii 表目錄 xiv 一、 研究背景 1 1 大腸直腸癌 1 1.1 簡介 1 1.2 腫瘤生成機制 2 1.3 癌症分期 3 2 Contactin 4 (CNTN4) 6 2.1 Contactin family 6 2.2 CNTN4之功能 6 2.3 CNTN4相關研究 7 3 實驗室先前CNTN4 相關研究 8 3.1 第三號染色體失異合性檢測 8 3.2 CNTN4抑癌功能之研究 8 4 Protein Tyrosine Phosphatase Receptor gamma (PTPRG) 8 4.1 PTPRG簡介 8 4.2 PTPRG於癌症相關研究 9 4.3 PTPRG與Contactin之關聯 9 5 Epidermal Growth Factor Receptor (EGFR) 10 5.1 EGFR 簡介 10 5.2 EGFR之相關機制與研究 10 6 β-catenin於大腸直腸癌之角色 11 6.1 β-catenin簡介 11 6.2 β-catenin相關調控路徑 11 7 Notch (Neurogenic locus notch homolog protein) 12 7.1 Notch簡介 12 7.2 NOTCH相關調控路徑 12 8 細胞週期 13 8.1 CDK、cyclin及細胞週期抑制因子 13 8.2 細胞週期檢查點 14 二、 研究目標 15 三、 材料與方法 16 1 細胞培養 16 1.1 細胞株 16 1.2 細胞培養 16 2 慢病毒轉導暫時性表現細胞株 17 3 RNA萃取 18 4 即時定量聚合酶連鎖反應 18 5 蛋白質萃取與定量 19 6 西方墨點法 19 6.1 蛋白質檢測 19 6.2 抗體清單 20 7 細胞週期分析 21 8 免疫螢光染色 21 9 RNA定序 22 9.1 樣品製備 22 9.2 次世代定序 22 10 生物資訊分析 23 11 生物資訊公開資料庫分析 23 12 統計方式 23 四、 研究結果 24 1. 利用公開資料庫分析CNTN4於大腸直腸癌表現與對病患存活率的影響 24 2. 生物資訊公開資料庫分析CNTN4之相關蛋白 24 3. 於HCT116單一穩定表現CNTN4細胞株利用RNA-Sequencing分析基因表現之差異 25 4. 將RNA-seq結果利用生物資訊資料庫分析CNTN4可能參與之調控路徑 25 5. 在不同大腸癌細胞株表現CNTN4降低EGFR mRNA與蛋白質表現 26 6. 探討CNTN4對於磷酸化激酶與其下游路經之調控 26 7. 探討CNTN4與c-MYC之關聯性 27 8. 慢病毒轉導使大腸直腸癌細胞株COLO205和HT29暫時性表現 CNTN4並其影響之調控路徑 28 9. 探討CNTN4與β-catenin之關聯性 29 10. 探討NOTCH訊號傳遞路徑與CNTN4之關聯性 29 11. 探討CNTN4對於細胞週期之影響及其調控機制 30 五、 討論 32 圖 37 表 65 參考文獻 79 附錄 86 | |
dc.language.iso | zh-TW | |
dc.title | 分析Contactin 4於大腸直腸癌所調控之抑癌分子機制 | zh_TW |
dc.title | Study of the molecular mechanisms underlying Contactin 4-mediated tumor suppression in colorectal cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 110-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蘇剛毅(Kang-Yi Su),郭靜穎(Ching-Ying Kuo),饒梓明(Tzu-Ming Jao) | |
dc.subject.keyword | 大腸直腸癌,Contactin 4,EGFR,c-MYC,β-catenin,NOTCH,細胞週期, | zh_TW |
dc.subject.keyword | Colorectal cancer,Contactin 4,EGFR,c-MYC,β-catenin,NOTCH,Cell cycle, | en |
dc.relation.page | 88 | |
dc.identifier.doi | 10.6342/NTU202204154 | |
dc.rights.note | 同意授權(限校園內公開) | |
dc.date.accepted | 2022-09-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
dc.date.embargo-lift | 2022-10-13 | - |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2709202212424700.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 10.37 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。